← Back to headlines
Karyopharm Stock Plummets After Xpovio Fails Endometrial Cancer Trial
Karyopharm Therapeutics' stock fell sharply after its drug Xpovio did not meet its primary endpoint in a Phase 3 clinical trial for advanced endometrial cancer.
30 Jul, 23:38 — 30 Jul, 23:38
Sources
Showing 1 of 1 sources
